Clinical Trial Update: Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial assessing AZD1152 (barasertib) in relapsed acute myeloid leukemia, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD1152 (barasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Myeloid Leukemia | Phase 1 | Status: COMPLETED